Patents by Inventor Jonathan Kipnis

Jonathan Kipnis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
    Patent number: 7351686
    Abstract: A vaccine for reducing disease progression, and/or protection of motor nerve degeneration, and/or protection from glutamate toxicity in motor neurone disease (MND), particularly amyotrophic lateral sclerosis (ALS), patients, comprising an active agent selected from the group consisting of Cop 1, a Cop 1-related peptide, a Cop 1-related polypeptide, and poly-Glu, Tyr. The active agent is preferably Cop 1 or poly-Glu, Tyr, and can be administered with or without an adjuvant.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: April 1, 2008
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Esther Yoles, Jonathan Kipnis
  • Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
    Publication number: 20050159336
    Abstract: Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
    Type: Application
    Filed: January 13, 2005
    Publication date: July 21, 2005
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Irun Cohen, Michael Sela, Eti Yoles, Jonathan Kipnis
  • Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
    Patent number: 6844314
    Abstract: Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: January 18, 2005
    Assignee: Yeda Research Development Co., Ltd.
    Inventors: Michal Eisenbach-Schwartz, Irun R. Cohen, Michael Sela, Eti Yoles, Jonathan Kipnis
  • The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
    Publication number: 20030004099
    Abstract: Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
    Type: Application
    Filed: January 22, 2001
    Publication date: January 2, 2003
    Inventors: Michael Eisenbach-schwartz, Irun R. Cohen, Michael Sela, Eti Yoles, Jonathan Kipnis
  • Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
    Publication number: 20020037848
    Abstract: Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
    Type: Application
    Filed: January 22, 2001
    Publication date: March 28, 2002
    Inventors: Michal Eisenbach-Schwartz, Eti Yoles, Jonathan Kipnis